Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Genome Editing: A Tool For Research and Therapy: Targeted genome editing hits the clinic


Targeted genome editing by engineered endonucleases allows the precise introduction of gene deletions and substitutions into the target genome. In 'Bench to Bedside', Keith Joung and his colleagues discuss how genome-editing technologies could be applied to engineer disease-associated somatic variation into human cell lines and disease models. This would allow the functional interpretation of such variants, which could then be applied to molecular diagnostics in the clinic. In 'Bedside to Bench', Angelo Lombardo and Luigi Naldini consider the potential applications of genome editing in the clinic, in which engineered endonucleases have been shown to be safe. Endonucleases could replace disease-associated genes with wild-type versions or be used to delete genes encoding receptors essential to viral host entry to prevent infection.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Figure 1: Exploiting targeted gene editing for therapeutic applications.

Katie Vicari/Nature Publishing Group


  1. Tebas, P. et al. N. Engl. J. Med. 370, 901–910 (2014).

    Article  CAS  Google Scholar 

  2. Holt, N. et al. Nat. Biotechnol. 28, 839–847 (2010).

    Article  CAS  Google Scholar 

  3. Genovese, P. et al. Nature 510, 235–240 (2014).

    Article  CAS  Google Scholar 

  4. Ciccia, A. & Elledge, S.J. Mol. Cell 40, 179–204 (2010).

    Article  CAS  Google Scholar 

  5. Liu, R. et al. Cell 86, 367–377 (1996).

    Article  CAS  Google Scholar 

  6. Hütter, G. et al. N. Engl. J. Med. 360, 692–698 (2009).

    Article  Google Scholar 

  7. Lombardo, A. et al. Nat. Biotechnol. 25, 1298–1306 (2007).

    Article  CAS  Google Scholar 

  8. Lombardo, A. et al. Nat. Methods 8, 861–869 (2011).

    Article  CAS  Google Scholar 

  9. Fischer, A., Hacein-Bey-Abina, S. & Cavazzana-Calvo, M. Gene 525, 170–173 (2013).

    Article  CAS  Google Scholar 

  10. Beerman, I., Seita, J., Inlay, M.A., Weissman, I.L. & Rossi, D.J. Cell Stem Cell 15, 37–50 (2014).

    Article  CAS  Google Scholar 

  11. Gabriel, R. et al. Nat. Biotechnol. 29, 816–823 (2011).

    Article  CAS  Google Scholar 

  12. Kim, H. & Kim, J.S. Nat. Rev. Genet. 15, 321–334 (2014).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Luigi Naldini.

Ethics declarations

Competing interests

The authors declare that they receive some research funding from Sangamo BioSciences to perform targeted genome editing with ZFNs and that they are inventors on filed patent applications on targeted genome editing.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lombardo, A., Naldini, L. Genome Editing: A Tool For Research and Therapy: Targeted genome editing hits the clinic. Nat Med 20, 1101–1103 (2014).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research